Monday, September 17, 2018

Curetis, not a Benjamin Graham Defensive stock

Curetis "a young, dynamic and creative molecular diagnostics company, we have specialized in simple and rapid solutions for the diagnosis of severe infectious diseases in hospitalized patients. We help to combat infections effectively and detect antibiotic resistance at an early stage."

2017 analysis: "As a loss-making company = too difficult pile. Price fell from 7,14 to 5 June 2016-June 2017"

Now in September 2018 the price is EUR 3,70.

"In April 2018, Curetis raised EUR 4.1 million in a private placement of equity shares and issued 854,166 new shares. In addition, Curetis secured access to an additional USD 10 million equity facility offered by Global Corporate Finance (GCF) in New York allowing the Company solely at its request to raise capital over a period of up to 36 months subject to certain pre-agreed floor pricing."

EUR 4.1 million / 854,166 = EUR 4,8 per placed share.

Book value = EUR 14,7m equity / 16m shares = 92 cents per share.

Do you speak Dutch? If so please opt-in at Thanks in advance! Comments, questions or E-mails welcome:

No comments: